SuO-Val-Cit-PAB-MMAE

SuO-Val-Cit-PAB-MMAE

• UNSPSC Description: SuO-Val-Cit-PAB-MMAE is a agent-linker conjugate for ADC by using the anti-mitotic agent, monomethyl auristatin E (MMAE, a tubulin inhibitor), linked via the peptide SuO-Val-Cit-PAB[1].
• Target Antigen: Drug-Linker Conjugates for ADC
• Type: ADC Related
• Related Pathways: Antibody-drug Conjugate/ADC Related
• Applications: Cancer-programmed cell death
• Field of Research: Cancer
• Assay Protocol: https://www.medchemexpress.com/SuO-Val-Cit-PAB-MMAE.html
• Purity: 99.24
• Solubility: DMSO : 50 mg/mL (ultrasonic;warming;heat to 60°C)
• Smiles: CC[C@H](C)[C@@H]([C@@H](CC(N1[C@@H](CCC1)[C@@H]([C@@H](C)C(N[C@H](C)[C@@H](O)C2=CC=CC=C2)=O)OC)=O)OC)N(C([C@H](C(C)C)NC([C@H](C(C)C)N(C(OCC3=CC=C(NC([C@H](CCCNC(N)=O)NC([C@H](C(C)C)NC(ON4C(CCC4=O)=O)=O)=O)=O)C=C3)=O)C)=O)=O)C
• Molecular Weight: 1264.51
• References & Citations: [1]Kamath AV, et al. Preclinical Pharmacokinetic Considerations for the Development of Antibody Drug Conjugates. Pharm Res. 2015 Nov;32(11):3470-9.
• Shipping Conditions: Dry Ice
• Storage Conditions: -80°C, stored under nitrogen
• Clinical Information: No Development Reported